Glucotrack Stock Performance
| GCTK Stock | USD 1.91 0.36 15.86% |
The company retains a Market Volatility (i.e., Beta) of 2.67, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, GlucoTrack will likely underperform. At this point, GlucoTrack has a negative expected return of -1.67%. Please make sure to check out GlucoTrack's maximum drawdown, accumulation distribution, as well as the relationship between the Accumulation Distribution and market facilitation index , to decide if GlucoTrack performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days GlucoTrack has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in March 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Last Split Factor 1:60 | Last Split Date 2025-06-16 |
1 | GlucoTrack Announces Special Shareholders Meeting for Equity Deal - The Globe and Mail | 11/04/2025 |
2 | Acquisition by Carter Erin Catherine of 2078 shares of GlucoTrack at 31.2 subject to Rule 16b-3 | 11/07/2025 |
3 | Head-To-Head Contrast Else Nutrn and GlucoTrack | 11/10/2025 |
4 | Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights | 11/13/2025 |
5 | Is GlucoTrack Inc. stock gaining market share - Weekly Profit Recap Smart Allocation Stock Tips - newser.com | 11/19/2025 |
6 | Why GlucoTrack Inc. stock remains on watchlists - July 2025 Outlook Daily Chart Pattern Signals - Newser | 12/04/2025 |
7 | Acquisition by Balo Andrew K of 3332 shares of GlucoTrack subject to Rule 16b-3 | 12/09/2025 |
8 | GlucoTrack Issues Investor Presentation Under Regulation FD - TipRanks | 12/29/2025 |
9 | GlucoTrack strengthens capital position with new private placement - TipRanks | 12/31/2025 |
10 | Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform | 01/29/2026 |
| Begin Period Cash Flow | 4.5 M | |
| Total Cashflows From Investing Activities | -104 K |
GlucoTrack | Build AI portfolio with GlucoTrack Stock |
GlucoTrack Relative Risk vs. Return Landscape
If you would invest 646.00 in GlucoTrack on November 3, 2025 and sell it today you would lose (455.00) from holding GlucoTrack or give up 70.43% of portfolio value over 90 days. GlucoTrack is currently does not generate positive expected returns and assumes 7.2065% risk (volatility on return distribution) over the 90 days horizon. In different words, 64% of stocks are less volatile than GlucoTrack, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
GlucoTrack Target Price Odds to finish over Current Price
The tendency of GlucoTrack Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.91 | 90 days | 1.91 | close to 99 |
Based on a normal probability distribution, the odds of GlucoTrack to move above the current price in 90 days from now is close to 99 (This GlucoTrack probability density function shows the probability of GlucoTrack Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 2.67 . This usually indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, GlucoTrack will likely underperform. Additionally GlucoTrack has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. GlucoTrack Price Density |
| Price |
Predictive Modules for GlucoTrack
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as GlucoTrack. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of GlucoTrack's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
GlucoTrack Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. GlucoTrack is not an exception. The market had few large corrections towards the GlucoTrack's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold GlucoTrack, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of GlucoTrack within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.7 | |
β | Beta against Dow Jones | 2.67 | |
σ | Overall volatility | 1.16 | |
Ir | Information ratio | -0.23 |
GlucoTrack Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GlucoTrack for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GlucoTrack can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| GlucoTrack generated a negative expected return over the last 90 days | |
| GlucoTrack has high historical volatility and very poor performance | |
| GlucoTrack may become a speculative penny stock | |
| GlucoTrack has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.6 M) with loss before overhead, payroll, taxes, and interest of (20 K). | |
| GlucoTrack currently holds about 3.85 M in cash with (12.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. | |
| Latest headline from globenewswire.com: Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform |
GlucoTrack Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GlucoTrack Stock often depends not only on the future outlook of the current and potential GlucoTrack's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GlucoTrack's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 371.9 K | |
| Cash And Short Term Investments | 5.6 M |
GlucoTrack Fundamentals Growth
GlucoTrack Stock prices reflect investors' perceptions of the future prospects and financial health of GlucoTrack, and GlucoTrack fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GlucoTrack Stock performance.
| Return On Equity | -14.91 | ||||
| Return On Asset | -2.26 | ||||
| Current Valuation | (2.5 M) | ||||
| Shares Outstanding | 910.69 K | ||||
| Price To Book | 0.75 X | ||||
| Gross Profit | (20 K) | ||||
| EBITDA | (21.98 M) | ||||
| Net Income | (22.6 M) | ||||
| Cash And Equivalents | 3.85 M | ||||
| Cash Per Share | 0.25 X | ||||
| Total Debt | 267 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 4.52 X | ||||
| Book Value Per Share | 3.06 X | ||||
| Cash Flow From Operations | (12.49 M) | ||||
| Earnings Per Share | (1,067) X | ||||
| Market Capitalization | 1.74 M | ||||
| Total Asset | 5.93 M | ||||
| Retained Earnings | (132.45 M) | ||||
| Working Capital | 4.49 M | ||||
About GlucoTrack Performance
By examining GlucoTrack's fundamental ratios, stakeholders can obtain critical insights into GlucoTrack's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that GlucoTrack is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.5 K | 3.9 K | |
| Return On Tangible Assets | (4.38) | (4.60) | |
| Return On Capital Employed | (3.59) | (3.41) | |
| Return On Assets | (4.38) | (4.60) | |
| Return On Equity | 2.00 | 2.10 |
Things to note about GlucoTrack performance evaluation
Checking the ongoing alerts about GlucoTrack for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GlucoTrack help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GlucoTrack generated a negative expected return over the last 90 days | |
| GlucoTrack has high historical volatility and very poor performance | |
| GlucoTrack may become a speculative penny stock | |
| GlucoTrack has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (22.6 M) with loss before overhead, payroll, taxes, and interest of (20 K). | |
| GlucoTrack currently holds about 3.85 M in cash with (12.49 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.25. | |
| Latest headline from globenewswire.com: Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform |
- Analyzing GlucoTrack's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GlucoTrack's stock is overvalued or undervalued compared to its peers.
- Examining GlucoTrack's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GlucoTrack's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GlucoTrack's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GlucoTrack's stock. These opinions can provide insight into GlucoTrack's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlucoTrack. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For more information on how to buy GlucoTrack Stock please use our How to buy in GlucoTrack Stock guide.You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlucoTrack. Market participants price GlucoTrack higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive GlucoTrack assessment requires weighing all these inputs, though not all factors influence outcomes equally.
The market value of GlucoTrack is measured differently than its book value, which is the value of GlucoTrack that is recorded on the company's balance sheet. Investors also form their own opinion of GlucoTrack's value that differs from its market value or its book value, called intrinsic value, which is GlucoTrack's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlucoTrack's market value can be influenced by many factors that don't directly affect GlucoTrack's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlucoTrack's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlucoTrack is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, GlucoTrack's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.